title: Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma.
abstract: Hyperthermic antiblastic perfusion/HAP) has been proven to be an effective neoadjuvant treatment in the treatment of advanced soft tissue limb sarcoma. As a matter of fact high percentage of limb sparing surgery, local control and functional results have been obtained wide this technique. Many antineoplastic drugs have been associated to hyperthermia by isolation limb perfusion, the aim of this paper was to describe the results obtained with doxorubicin in association to hyperthermia with or without Tumor Necrosis Factor (TNF) alpha in order to identify the most effective regimen in the multidisciplinary treatment of soft tissue limb sarcoma. A total of 106 patients have been evaluated. Three different study were performed: the first was a phase I study carried out in order to assess the maximum tolerable dose (MTD) of doxorubicin during HAP; the second was a phase II study with doxorubicin, and the third was a phase I - II study aimed at evaluating the MTD and tumor response of TNF alpha in association to doxorubicin and hyperthermia. Grade IV limb toxicity was recorded in 11 patients ( 4 in trial A, 3 in trial B, and 4 in trial C). The grade of limb reaction was strictly related to TNF dosage (> 1 mg) and temperature level (> 41.5 degrees C), therefore the best regimen is represented by temperature level not exceeding 41.5 degrees C and 1 mg of TNFalpha. The trimodality association (TNF, doxorubicin and hyperthermia) was proven to be the best regimen able to obtain a 77% of objective response (complete response, 22%) and a 77% of limb sparing in patients candidate to amputation. The results above mentioned showed the HAP with doxorubicin and TNFalpha (1 mg) is a very effective neoadjuvant treatment in the multidisciplinary treatment of advanced soft tissue limb sarcoma.
authors.affiliation: Department of Surgery, Regina Elena National Cancer Institute, Rome Italy. difilippo@ifo.it
authors.forename: F
authors.initials: F
authors.lastname: Di Filippo
authors.forename: R
authors.initials: R
authors.lastname: Garinei
authors.forename: M
authors.initials: M
authors.lastname: Anzà
authors.forename: F
authors.initials: F
authors.lastname: Cavaliere
authors.forename: D
authors.initials: D
authors.lastname: Giannarelli
authors.forename: P P
authors.initials: PP
authors.lastname: Cagol
authors.forename: C R
authors.initials: CR
authors.lastname: Rossi
authors.forename: M
authors.initials: M
authors.lastname: Santinami
authors.forename: M
authors.initials: M
authors.lastname: Deraco
authors.forename: C
authors.initials: C
authors.lastname: Botti
authors.forename: P
authors.initials: P
authors.lastname: Perri
authors.forename: S
authors.initials: S
authors.lastname: Di Filippo
authors.forename: L
authors.initials: L
authors.lastname: Piarulli
authors.forename: P
authors.initials: P
authors.lastname: Bruno
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D010478:Chemotherapy, Cancer, Regional Perfusion; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage*; D005121:Extremities / Q000473:pathology; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality; D012737:Sex Factors; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000401:mortality; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D014409:Tumor Necrosis Factor-alpha; D004317:Doxorubicin